1️⃣ Getinge just exposed the new pharma capex weak spot
Getinge said on April 21 that Q1 adjusted EBITA fell 18% to SEK 824M, with softer orders for washers, isolators and sterilizers as pharma customers delayed project spending, even while Life Science sales still grew 16% organically.
💡 Why it matters
Those categories sit close to sterile capacity buildouts. If project equipment slips while consumables still move, expansion plans are being pushed right rather than cancelled outright.
☕ Coffee talk
Washers and isolators are not impulse buys. Which 2026 capacity plans are quietly moving right?
2️⃣ Polish reimbursement cuts are already changing diagnostics M&A
Diagnostyka said on April 21 it will limit acquisitions of publicly funded imaging assets after Poland introduced a 50% reimbursement cap for above-contract procedures and cut CT and MRI rates.
💡 Why it matters
This is reimbursement pressure showing up in strategy, not just margins. Fewer roll-ups means lower deal appetite and more value shifting toward private-pay diagnostics.
☕ Coffee talk
When imaging roll-ups pause on a tariff change, what does that say about every reimbursement-driven thesis in Europe?
3️⃣ CDMO buyers are moving down to packaging now
Alcami agreed on April 21 to buy Tjoapack, adding 23 packaging lines across Tennessee and the Netherlands plus EU Qualified Person release to build a transatlantic CDMO platform.
💡 Why it matters
Packaging used to sit at the back of the value chain. Now redundancy, release and fewer supplier handoffs are part of the outsourcing pitch.
☕ Coffee talk
If packaging is now strategic infrastructure, how much of CDMO selection is really about geography and release rights?